Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Hold” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given an average recommendation of “Hold” by the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $70.75.

Several equities research analysts recently issued reports on PBH shares. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Finally, Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $47.65 on Friday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a twelve month low of $42.62 and a twelve month high of $85.57. The stock’s 50 day moving average is $52.19 and its 200-day moving average is $59.67. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of 12.19, a PEG ratio of 1.58 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. During the same quarter last year, the company posted $1.32 EPS. The company’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.45 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA grew its stake in Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after purchasing an additional 60,496 shares during the period. Nordea Investment Management AB grew its stake in Prestige Consumer Healthcare by 547.4% in the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after purchasing an additional 520,186 shares during the period. Leeward Investments LLC MA grew its stake in Prestige Consumer Healthcare by 23.3% in the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock valued at $23,894,000 after purchasing an additional 73,162 shares during the period. JPMorgan Chase & Co. grew its stake in Prestige Consumer Healthcare by 30.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock valued at $28,656,000 after purchasing an additional 106,224 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 1.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after purchasing an additional 21,085 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).